FDA Clears AN2 Therapeutics Epetraborole Trial for M. abscessus Lung Disease

Reuters

Jan 12

FDA Clears AN2 <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Epetraborole Trial for M. abscessus Lung Disease

AN2 Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared Oregon Health & Science University's (OHSU) Investigational New Drug $(IND)$ application to proceed with a 90-patient investigator-initiated trial of epetraborole in patients with Mycobacterium abscessus lung disease. The multicenter, randomized, double-blind, placebo-controlled study will be led by Dr. Kevin Winthrop at OHSU and conducted across an estimated 10-15 sites in the United States. There are currently no FDA-approved therapies for M. abscessus lung disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260112479198) on January 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2602151416"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2602151416\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2602151416?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602151416","market":"fut","top_or_hot":-1,"title":"FDA Clears AN2 Therapeutics Epetraborole Trial for M. abscessus Lung Disease","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      FDA Clears AN2 <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Epetraborole Trial for M. abscessus Lung Disease\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        AN2 Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared Oregon Health &amp; Science University's (OHSU) Investigational New Drug <a href=\"https://laohu8.com/S/IND\">$(IND)$</a> application to proceed with a 90-patient investigator-initiated trial of epetraborole in patients with Mycobacterium abscessus lung disease. The multicenter, randomized, double-blind, placebo-controlled study will be led by Dr. Kevin Winthrop at OHSU and conducted across an estimated 10-15 sites in the United States. There are currently no FDA-approved therapies for M. abscessus lung disease.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260112479198) on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Clears AN2 Therapeutics Epetraborole Trial for M. abscessus Lung Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Clears AN2 Therapeutics Epetraborole Trial for M. abscessus Lung Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-12 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      FDA Clears AN2 <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Epetraborole Trial for M. abscessus Lung Disease\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        AN2 Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared Oregon Health &amp; Science University's (OHSU) Investigational New Drug <a href=\"https://laohu8.com/S/IND\">$(IND)$</a> application to proceed with a 90-patient investigator-initiated trial of epetraborole in patients with Mycobacterium abscessus lung disease. The multicenter, randomized, double-blind, placebo-controlled study will be led by Dr. Kevin Winthrop at OHSU and conducted across an estimated 10-15 sites in the United States. There are currently no FDA-approved therapies for M. abscessus lung disease.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260112479198) on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ANTX","symbol_name":"AN2 Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL3LVj1:1","article_id":"2602151416","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602151416","pubTimestamp":1768219329,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"AN2 Therapeutics Inc. announced that the U.S. Food and Drug Administration  has cleared Oregon Health & Science University's  Investigational New Drug  application to proceed with a 90-patient investigator-initiated trial of epetraborole in patients with Mycobacterium abscessus lung disease. The multicenter, randomized, double-blind, placebo-controlled study will be led by Dr. Kevin Winthrop at OHSU and conducted across an estimated 10-15 sites in the United States. There are currently no FDA-approved therapies for M. abscessus lung disease.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on January 12, 2026, and is solely responsibl","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ANTX":"AN2 Therapeutics, Inc.","BK4007":"制药"},"translate_title":"FDA批准AN2 Therapeutics Epetraborole治疗脓肿分枝杆菌肺病的试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANTX":0.9},"content_text":"FDA Clears AN2 Therapeutics Epetraborole Trial for M. abscessus Lung Disease\n    \n\n        AN2 Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared Oregon Health & Science University's (OHSU) Investigational New Drug $(IND)$ application to proceed with a 90-patient investigator-initiated trial of epetraborole in patients with Mycobacterium abscessus lung disease. The multicenter, randomized, double-blind, placebo-controlled study will be led by Dr. Kevin Winthrop at OHSU and conducted across an estimated 10-15 sites in the United States. There are currently no FDA-approved therapies for M. abscessus lung disease.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260112479198) on January 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}